Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.

Lam S, Mandrekar SJ, Gesthalter Y, Allen Ziegler KL, Seisler DK, Midthun DE, Mao JT, Aubry MC, McWilliams A, Sin DD, Shaipanich T, Liu G, Johnson E, Bild A, Lenburg ME, Ionescu DN, Mayo J, Yi JE, Tazelaar H, Harmsen WS, Smith J, Spira AE, Beane J, Limburg PJ, Szabo E; Cancer Prevention Network.

Cancer Prev Res (Phila). 2016 Dec;9(12):906-914. Epub 2016 Sep 22.

2.

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ.

Cancer. 2012 Nov 1;118(21):5358-65. doi: 10.1002/cncr.27528. Epub 2012 Mar 20.

3.

Endpoints in phase II trials for advanced non-small cell lung cancer.

Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA.

J Thorac Oncol. 2010 Jan;5(1):3-9. doi: 10.1097/JTO.0b013e3181c0a313.

4.

Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study.

Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR.

J Thorac Oncol. 2009 Apr;4(4):479-85.

Supplemental Content

Loading ...
Support Center